scholarly journals Serine hydroxymethyltransferase 2 expression promotes tumorigenesis in rhabdomyosarcoma with 12q13-14 amplification

Author(s):  
Thanh H. Nguyen ◽  
Prasantha L. Vemu ◽  
Gregory E. Hoy ◽  
Salah Boudjadi ◽  
Bishwanath Chatterjee ◽  
...  
1983 ◽  
Vol 258 (21) ◽  
pp. 13155-13159 ◽  
Author(s):  
F Gavilanes ◽  
D Peterson ◽  
B Bullis ◽  
L Schirch

Oncogene ◽  
2021 ◽  
Author(s):  
Jian Chen ◽  
Risi Na ◽  
Chao Xiao ◽  
Xiao Wang ◽  
Yupeng Wang ◽  
...  

Abstract5-Fluorouracil (5-FU)-based chemotherapy is the first-line treatment for colorectal cancer (CRC) but is hampered by chemoresistance. Despite its impact on patient survival, the mechanism underlying chemoresistance against 5-FU remains poorly understood. Here, we identified serine hydroxymethyltransferase-2 (SHMT2) as a critical regulator of 5-FU chemoresistance in CRC. SHMT2 inhibits autophagy by binding cytosolic p53 instead of metabolism. SHMT2 prevents cytosolic p53 degradation by inhibiting the binding of p53 and HDM2. Under 5-FU treatment, SHMT2 depletion promotes autophagy and inhibits apoptosis. Autophagy inhibitors decrease low SHMT2-induced 5-FU resistance in vitro and in vivo. Finally, the lethality of 5-FU treatment to CRC cells was enhanced by treatment with the autophagy inhibitor chloroquine in patient-derived and CRC cell xenograft models. Taken together, our findings indicate that autophagy induced by low SHMT2 levels mediates 5-FU resistance in CRC. These results reveal the SHMT2–p53 interaction as a novel therapeutic target and provide a potential opportunity to reduce chemoresistance.


2005 ◽  
Vol 45 (1) ◽  
pp. 71-82 ◽  
Author(s):  
Jan K. Schjoerring ◽  
Gisela Mäck ◽  
Kent Høier Nielsen ◽  
Søren Husted ◽  
Akira Suzuki ◽  
...  

1987 ◽  
Vol 262 (12) ◽  
pp. 5499-5509 ◽  
Author(s):  
F. Martini ◽  
S. Angelaccio ◽  
S. Pascarella ◽  
D. Barra ◽  
F. Bossa ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document